Drug Profile


Alternative Names: BGC 9331; ZD 9331

Latest Information Update: 06 Dec 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; BTG; Cancer Research UK Centre for Cancer Therapeutics
  • Developer BTG
  • Class Antineoplastics; Tetrazoles
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastric cancer; Ovarian cancer; Pancreatic cancer
  • Discontinued Colorectal cancer; Solid tumours

Most Recent Events

  • 06 Dec 2010 No development reported - Phase-I/II for Gastric cancer in Europe (IV-infusion)
  • 06 Dec 2010 No development reported - Phase-II for Gastric cancer in Czech Republic (IV-infusion)
  • 06 Dec 2010 No development reported - Phase-II for Gastric cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top